A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2021

Primary Completion Date

December 29, 2022

Study Completion Date

August 23, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

BIOLOGICAL

Engensis

Lyophilized biologic to be reconstituted containing Engensis

OTHER

Placebo

Injectable Liquid

Trial Locations (2)

Austin Neuromuscular Center, Austin

Hanyang University Medical Center, Seoul

All Listed Sponsors

lead

Helixmith Co., Ltd.

INDUSTRY

NCT05176093 - A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter